Syngene (established in 1993) as a Biocon subsidiary is India’s first Contract Research Organization (CRO) which expanded later to be an integrated service provider offering end-to-end drug discovery, development, and manufacturing services on a single platform (CRAMS). Total research & manufacturing infrastructure for the company is spread across 1.9 million square feet across locations.
Financial Results:
Syngene International Ltd reported Revenues for Q4FY24 of ₹917.00 Crores down from ₹994.00 Crore year on year, a fall of 7.75%.
Total Expenses for Q4FY24 of ₹724.00 Crores down from ₹786.00 Crores year on year, a fall of 7.89%.
Consolidated Net Profit of ₹189.00 Crores up 5.59% from ₹179.00 Crores in the same quarter of the previous year.
The Earnings per Share is ₹4.69, up 5.39% from ₹4.45 in the same quarter of the previous year.
*It is important to note that the way the results have been accounted for are slightly different than the ones the companies may choose to publish.
*The presented data is automatically generated. It may occasionally generate incorrect information.